Reported Consolidated quarterly numbers for Marksans Pharma are:Net Sales at Rs 361.20 crore in September 2021 up 1.33% from Rs. 356.47 crore in September 2020.
Quarterly Net Profit at Rs. 46.29 crore in September 2021 down 8.76% from Rs. 50.73 crore in September 2020.
EBITDA stands at Rs. 68.67 crore in September 2021 down 20.91% from Rs. 86.82 crore in September 2020.
Marksans Pharma EPS has decreased to Rs. 1.11 in September 2021 from Rs. 1.21 in September 2020.
Marksans Pharma shares closed at 67.35 on November 09, 2021 (NSE) and has given -13.49% returns over the last 6 months and 30.65% over the last 12 months.
| Marksans Pharma | | Consolidated Quarterly Results | in Rs. Cr. |
|
| Sep'21 | Jun'21 | Sep'20 | | Net Sales/Income from operations | 361.20 | 348.96 | 356.47 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 361.20 | 348.96 | 356.47 | | EXPENDITURE | | Consumption of Raw Materials | 170.21 | 113.34 | 117.64 | | Purchase of Traded Goods | 32.94 | 6.33 | 52.72 | | Increase/Decrease in Stocks | -27.77 | 42.63 | -6.67 | | Power & Fuel | -- | -- | -- | | Employees Cost | 54.79 | 49.05 | 43.88 | | Depreciation | 7.39 | 7.47 | 18.99 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 70.93 | 60.28 | 65.75 | | P/L Before Other Inc., Int., Excpt. Items & Tax | 52.71 | 69.87 | 64.16 | | Other Income | 8.57 | 5.88 | 3.67 | | P/L Before Int., Excpt. Items & Tax | 61.28 | 75.75 | 67.83 | | Interest | 1.50 | 0.97 | 1.93 | | P/L Before Exceptional Items & Tax | 59.78 | 74.78 | 65.90 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | 59.78 | 74.78 | 65.90 | | Tax | 13.49 | 12.18 | 15.16 | | P/L After Tax from Ordinary Activities | 46.29 | 62.60 | 50.73 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 46.29 | 62.60 | 50.73 | | Minority Interest | -- | -- | -- | | Share Of P/L Of Associates | -- | -- | -- | | Net P/L After M.I & Associates | 46.29 | 62.60 | 50.73 | | Equity Share Capital | 40.93 | 40.93 | 40.93 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 1.11 | 1.51 | 1.21 | | Diluted EPS | 1.11 | 1.51 | 1.21 | | EPS After Extra Ordinary | | Basic EPS | 1.11 | 1.51 | 1.21 | | Diluted EPS | 1.11 | 1.51 | 1.21 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|